Endocyte Stock Doubles In A Day, But Did Someone Know?

 | Apr 17, 2012 05:38AM ET

Endocyte, Inc. (ECYT) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its technology to create small molecule drug conjugates (SMDCs), and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, primarily to healthy cells

This is a note that examines order flow -- one of the most misused and over diagnosed trading signals in the options market. Let's take a close look at how option order flow can be protected, hidden, anonymously and electronically negotiated and ultimately, how finding information inside of it is close to impossible when its information is hidden appropriately.

Let's start with the news yesterday:

(Reuters) - Endocyte Inc said Merck & Co Inc had acquired the development and marketing rights of its experimental cancer drug, the latest in the string of licensing deals by the No. 2 U.S. drugmaker to beef up its cancer drug pipeline.

Shares of Endocyte, which had a market capitalization of about $136.18 million before the deal, more than doubled in value to $8.20 in early Monday trade. The stock was the biggest percentage gainer on the Nasdaq.

Endocyte, which is responsible for a majority of the funding and completion of the ovarian cancer trial, will receive $120 million in cash and up to $880 million in milestone payments.

"We also believe that this transaction definitely cracks the door open for an eventual acquisition by Merck, if they like what they see in the next couple of years ...," Cowen and Co analyst Simos Simeonidis said in a note to clients.

Source: Endocyte jumps on plans for cancer drug candidate

OK, so we have the news out of the way... let's focus on order flow and some of the rather fine intricacies. First, let's look to the Options Tab as of today, below.